Sequoia Capital, founded in 1972 and based in Menlo Park, California, is a prominent venture capital firm that invests in early to growth stage companies across various sectors, including technology, healthcare, financial services, and consumer services. The firm specializes in supporting startups and emerging growth companies, typically investing between $100,000 and $1 million in seed companies, $1 million to $10 million in early ventures, and $10 million to $100 million in growth investments. Sequoia Capital operates globally, with a presence in regions such as Israel, China, and Southeast Asia, and has built a diverse portfolio that includes notable companies like Airbnb, Alibaba, and JD.com. The firm emphasizes a partnership approach with entrepreneurs, leveraging decades of experience to guide them from initial concept through to public offering and beyond.
Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.
NuProbe, Inc. is an early-stage molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the company has developed a unique platform utilizing genetic toehold probes for quantitative PCR (qPCR) mutation detection. This innovative probe technology offers a Sample-In Answer-Out (SIAO) solution that integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatics interpretations, streamlining the diagnostic process.
Grit Science
Series A in 2022
Grit Science is a gene therapeutics firm, that engages in the R&D of liver genes.
Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Developer of gene sequencing technology designed to promote the development of precision medicine. The company's business scope covers software and hardware for sequencers, sample processing, consumables, reagents and data processing, enabling genetic sequencing to be a routine detection and diagnostic tool for medical industry.
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.
EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.
PackGene Biotech, LLC develops viral vectors for gene therapies. The company offers adeno-associated virus (AAV) vector cloning/packaging services. PackGene Biotech, LLC is based in the United States.
Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.
Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.
NuProbe, Inc. is an early-stage molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the company has developed a unique platform utilizing genetic toehold probes for quantitative PCR (qPCR) mutation detection. This innovative probe technology offers a Sample-In Answer-Out (SIAO) solution that integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatics interpretations, streamlining the diagnostic process.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
PackGene Biotech, LLC develops viral vectors for gene therapies. The company offers adeno-associated virus (AAV) vector cloning/packaging services. PackGene Biotech, LLC is based in the United States.
EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.
Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.
MedGenome Labs Private Ltd. specializes in molecular genetic diagnostic testing, utilizing advanced technologies such as Sanger sequencing and next-generation sequencing to support personalized healthcare. The company offers a comprehensive range of genetic tests, including exome, whole genome, and mitochondrial genome sequencing, alongside various disease panels. These panels focus on hereditary cancers, somatic mutations in tumors, and genetic conditions affecting cardiac, eye, and neuromuscular health. Additionally, MedGenome provides targeted tests for genetic mutations linked to non-syndromic deafness and autism spectrum disorders. The company also maintains OncoMD, a database of cancer-related mutations sourced from peer-reviewed research. MedGenome's services are designed to guide clinicians in identifying appropriate treatment options based on genetic variations and assessing disease risk. Established in 2013 and headquartered in Chennai, India, MedGenome operates as a subsidiary of SciGenom Labs Pvt Ltd and collaborates strategically with Denali Therapeutics to enhance its research capabilities.
Adagene (Suzhou) Limited is a clinical-stage biotechnology company based in Suzhou, China, focused on antibody discovery and engineering. The company specializes in developing immuno-oncology antibodies that target novel epitopes, utilizing its proprietary Smart Antibody Technology. This technology enhances the success rates of antibody development, significantly shortens the time required to bring products to market, and lowers associated costs. Adagene's offerings extend beyond therapeutic applications, as its technology is also applicable in diagnostics and research, aiming to advance the field of immunotherapy and improve patient outcomes. Founded in 2011, Adagene continues to innovate in the biopharmaceutical sector.
ViGeneron GmbH specializes in developing gene therapies aimed at treating ophthalmic diseases, particularly those with significant unmet medical needs. Founded in 2017 and based in Starnberg, Germany, the company utilizes two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV, enhances transduction efficiency and allows for less invasive intravitreal treatment administration. The second platform, REVeRT, addresses diseases linked to mutations in large genes. ViGeneron's innovative approach aims to generate full-length proteins with high precision, facilitating the advancement of novel therapies for retinal disorders. The company also seeks partnerships with leading biopharmaceutical firms to expand its impact in other disease areas.
Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.
Cullgen Inc. is a biopharmaceutical company based in San Diego, California, established in 2018. The company focuses on developing innovative new chemical entities (NCEs) aimed at treating diseases that currently lack effective therapeutic options. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins. This approach is particularly significant for addressing cancer, inflammatory, and autoimmune diseases, including targets that have been deemed undruggable. By providing novel therapeutic strategies, Cullgen aims to enhance drug discovery and offer new avenues for treating debilitating conditions.
BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.
BrightGene Bio-medical technology Co.,Ltd., is a leading Chinese biopharmaceutical company in small molecules and nucleotide drugs areas. Advised by China-based venture capital fund Laurel Venture Capital, BrightGene invests in all stage therapeutics and innovations.
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.
NextCODE Health LLC is a clinical diagnostics company specializing in sequence-based genomics. It offers a platform that assists healthcare professionals in obtaining clinical insights for rapid disease diagnosis. The company provides a range of services, including data analysis, genome interpretation, data mining, and sequencing services, both clinical and non-clinical. Founded on technology developed at deCODE genetics over 16 years, NextCODE focuses on integrating genome sequence data into patient care. Based in Cambridge, Massachusetts, the company was acquired by WuXi PharmaTech in 2015 and underwent a rebranding to Genuity Science in 2020. Through its innovative solutions, NextCODE aims to enhance the speed and accuracy of identifying genetic causes of diseases.
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.
NuProbe, Inc. is an early-stage molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the company has developed a unique platform utilizing genetic toehold probes for quantitative PCR (qPCR) mutation detection. This innovative probe technology offers a Sample-In Answer-Out (SIAO) solution that integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatics interpretations, streamlining the diagnostic process.
Adagene (Suzhou) Limited is a clinical-stage biotechnology company based in Suzhou, China, focused on antibody discovery and engineering. The company specializes in developing immuno-oncology antibodies that target novel epitopes, utilizing its proprietary Smart Antibody Technology. This technology enhances the success rates of antibody development, significantly shortens the time required to bring products to market, and lowers associated costs. Adagene's offerings extend beyond therapeutic applications, as its technology is also applicable in diagnostics and research, aiming to advance the field of immunotherapy and improve patient outcomes. Founded in 2011, Adagene continues to innovate in the biopharmaceutical sector.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
NextCODE Health LLC is a clinical diagnostics company specializing in sequence-based genomics. It offers a platform that assists healthcare professionals in obtaining clinical insights for rapid disease diagnosis. The company provides a range of services, including data analysis, genome interpretation, data mining, and sequencing services, both clinical and non-clinical. Founded on technology developed at deCODE genetics over 16 years, NextCODE focuses on integrating genome sequence data into patient care. Based in Cambridge, Massachusetts, the company was acquired by WuXi PharmaTech in 2015 and underwent a rebranding to Genuity Science in 2020. Through its innovative solutions, NextCODE aims to enhance the speed and accuracy of identifying genetic causes of diseases.
MedGenome Labs Private Ltd. specializes in molecular genetic diagnostic testing, utilizing advanced technologies such as Sanger sequencing and next-generation sequencing to support personalized healthcare. The company offers a comprehensive range of genetic tests, including exome, whole genome, and mitochondrial genome sequencing, alongside various disease panels. These panels focus on hereditary cancers, somatic mutations in tumors, and genetic conditions affecting cardiac, eye, and neuromuscular health. Additionally, MedGenome provides targeted tests for genetic mutations linked to non-syndromic deafness and autism spectrum disorders. The company also maintains OncoMD, a database of cancer-related mutations sourced from peer-reviewed research. MedGenome's services are designed to guide clinicians in identifying appropriate treatment options based on genetic variations and assessing disease risk. Established in 2013 and headquartered in Chennai, India, MedGenome operates as a subsidiary of SciGenom Labs Pvt Ltd and collaborates strategically with Denali Therapeutics to enhance its research capabilities.
Genesis Colors Limited, established in 1998 and based in Gurugram, India, is a prominent player in the fashion industry, specializing in the design, manufacture, and distribution of a diverse range of apparel and lifestyle products. The company is known for its well-established brands, including Satya Paul, renowned for its innovative sarees and vibrant prints, and Bwitch, which focuses on premium lingerie. Genesis Colors also holds the marketing and distribution rights for several international luxury labels, including Paul Smith, Bottega Veneta, Jimmy Choo, Armani, Furla, Tumi, Crabtree & Evelyn, and Michael Kors. Products are distributed through boutiques, multi-brand stores, and shop-in-shops across major cities in India, catering to various consumer preferences. The company prides itself on its modern design studio, where experienced in-house designers create a compelling array of garments and accessories that blend traditional and contemporary styles.
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
MedGenome Labs Private Ltd. specializes in molecular genetic diagnostic testing, utilizing advanced technologies such as Sanger sequencing and next-generation sequencing to support personalized healthcare. The company offers a comprehensive range of genetic tests, including exome, whole genome, and mitochondrial genome sequencing, alongside various disease panels. These panels focus on hereditary cancers, somatic mutations in tumors, and genetic conditions affecting cardiac, eye, and neuromuscular health. Additionally, MedGenome provides targeted tests for genetic mutations linked to non-syndromic deafness and autism spectrum disorders. The company also maintains OncoMD, a database of cancer-related mutations sourced from peer-reviewed research. MedGenome's services are designed to guide clinicians in identifying appropriate treatment options based on genetic variations and assessing disease risk. Established in 2013 and headquartered in Chennai, India, MedGenome operates as a subsidiary of SciGenom Labs Pvt Ltd and collaborates strategically with Denali Therapeutics to enhance its research capabilities.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Lifecode, Inc. is a molecular diagnostics company specializing in next-generation sequencing (NGS) technology, particularly in the field of oncology. Based in Foster City, California, the company develops a range of NGS-based cancer assays, including its flagship product, the Lifecode Pan Cancer Somatic Panel, designed for use in metastatic and rare cancers, as well as for patients who have exhausted standard treatment options or are exploring clinical trials. Lifecode aims to facilitate informed treatment decisions by providing clinical information to healthcare providers. To address the complexities of genomic data interpretation, Lifecode has assembled a skilled team with expertise in various scientific disciplines, including data science and molecular biology. The company is supported by funding from prominent investors, and it operates with a dual focus on software development and clinical laboratory services. Lifecode’s innovative approach is positioned to enhance personalized cancer care through accessible and interpretable genomic insights.
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
BGI Tech Solutions Co., Ltd., founded in 2012 and headquartered in Shenzhen, China, is a leading biotechnology company specializing in advanced life sciences technology. The company offers a wide range of services, including bioinformatics, genetic testing, and agricultural genomics research. BGI Tech operates lab facilities in Hong Kong, Wuhan, and Sacramento, and has a global service network that spans over 100 countries and regions. With collaborations involving more than 10,000 organizations and 30,000 partners, BGI Tech supports numerous research projects, including large-scale international genome initiatives. The company is committed to developing integrated omics platforms and aims to address various challenges in health, agriculture, energy, and environmental sectors, thereby contributing to scientific advancement and improving societal well-being.
BGI Tech Solutions Co., Ltd., founded in 2012 and headquartered in Shenzhen, China, is a leading biotechnology company specializing in advanced life sciences technology. The company offers a wide range of services, including bioinformatics, genetic testing, and agricultural genomics research. BGI Tech operates lab facilities in Hong Kong, Wuhan, and Sacramento, and has a global service network that spans over 100 countries and regions. With collaborations involving more than 10,000 organizations and 30,000 partners, BGI Tech supports numerous research projects, including large-scale international genome initiatives. The company is committed to developing integrated omics platforms and aims to address various challenges in health, agriculture, energy, and environmental sectors, thereby contributing to scientific advancement and improving societal well-being.
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Lifecode, Inc. is a molecular diagnostics company specializing in next-generation sequencing (NGS) technology, particularly in the field of oncology. Based in Foster City, California, the company develops a range of NGS-based cancer assays, including its flagship product, the Lifecode Pan Cancer Somatic Panel, designed for use in metastatic and rare cancers, as well as for patients who have exhausted standard treatment options or are exploring clinical trials. Lifecode aims to facilitate informed treatment decisions by providing clinical information to healthcare providers. To address the complexities of genomic data interpretation, Lifecode has assembled a skilled team with expertise in various scientific disciplines, including data science and molecular biology. The company is supported by funding from prominent investors, and it operates with a dual focus on software development and clinical laboratory services. Lifecode’s innovative approach is positioned to enhance personalized cancer care through accessible and interpretable genomic insights.
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Navigenics, Inc. helps educate and empower individuals and their physicians with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics' lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures.
Vical's core technology grew out of a chance discovery and provided the cornerstones for two new biopharmaceutical industry sectors: DNA vaccines and non-viral gene therapy.
Vical's management systematically leveraged that technology into a broad portfolio of independent and partnered product development programs. The first products for animal health are on the market. The first human products are approaching.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.